辉瑞(PFE)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

PFE 辉瑞

已收盘 12-15 16:00:00 EST

26.43

+0.58

+2.24%

盘后26.39

-0.04-0.15%

19:59 EST

最高26.65	最低25.81	成交量6,036万
今开25.82	昨收25.85	日振幅3.25%
总市值1,503亿	流通市值1,500亿	总股本56.86亿
成交额15.90亿	换手率1.06%	流通股本56.76亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"PFE","market":"US","secType":"STK","nameCN":"辉瑞","latestPrice":26.43,"timestamp":1765832400000,"preClose":25.85,"halted":0,"volume":60359978,"hourTrading":{"tag":"盘后","latestPrice":26.3897,"preClose":26.43,"latestTime":"19:59 EST","volume":3126550,"amount":82626332.6181,"timestamp":1765846781736},"delay":0,"floatShares":5675908374,"shares":5685707552,"eps":1.726245,"marketStatus":"已收盘","change":0.58,"latestTime":"12-15 16:00:00 EST","open":25.82,"high":26.65,"low":25.81,"amount":1590404839.72937,"amplitude":0.032495,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":1.726245,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1765875600000},"marketStatusCode":5,"adr":0,"adrRate":0,"listingDate":-819144000000,"exchange":"NYSE","adjPreClose":25.85,"dividendRate":0.064321,"preHourTrading":{"tag":"盘前","latestPrice":25.83,"preClose":25.85,"latestTime":"09:29 EST","volume":117893,"amount":3052276.649604,"timestamp":1765808975107},"postHourTrading":{"tag":"盘后","latestPrice":26.3897,"preClose":26.43,"latestTime":"19:59 EST","volume":3126550,"amount":82626332.6181,"timestamp":1765846781736},"volumeRatio":1.374947,"optionData":{"bulkOrders":[{"symbol":"PFE","call":false,"expireDate":1768539600000,"strike":"25.0","timestamp":1765823204249,"price":0.26,"volume":2500,"amount":65000,"type":"+"},{"symbol":"PFE","call":false,"expireDate":1766120400000,"strike":"25.0","timestamp":1765823204249,"price":0.07,"volume":2500,"amount":17500,"type":"-"}]},"impliedVol":0.2849,"impliedVolPercentile":0.364},"requestUrl":"/m/hq/s/PFE","defaultTab":"news","newsList":[{"id":"2591667541","title":"突发！辉瑞21亿美元买走中国减肥药","url":"https://stock-news.laohu8.com/highlight/detail?id=2591667541","media":"药闻社","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591667541?lang=zh_cn&edition=full","pubTime":"2025-12-14 23:22","pubTimestamp":1765725731,"startTime":"0","endTime":"0","summary":"最近减肥药赛道可真热闹，上个月辉瑞刚砸下100亿美元收购Metsera，如今又巨资锁定中国小分子减肥药。在今年中国创新药飞涨的行情中，辉瑞接洽国内药企洽谈减肥药BD出海的小作文层出不穷。从今年的数据看，礼来的GLP-1双靶点药物替尔泊肽今年前三季度销售额高达186.8亿美元，全年有望突破350亿美元，拿下GLP-1RA减肥药57%的市场份额。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251214232543a6a193f2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251214232543a6a193f2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1023059063.AUD","BK4585","SG9999002224.SGD","LU1883839398.USD","BK4534","BK4533","SG9999001176.SGD","LU0868494617.USD","BK4568","IE00B19Z3581.USD","IE000M9KFDE8.USD","BK4588","LU0225771236.USD","LU1066051498.USD","SG9999013999.USD","PFE","SG9999003800.SGD","IE0002270589.USD","LU0306806265.USD","LU0289739699.SGD","SGXZ57979304.SGD","LU0122379950.USD","IE00BLSP4452.SGD","IE00BLSP4239.USD","LU0234572021.USD","BK4550","LU0306807586.USD","IE00BBT3K403.USD","BK4599","LU0058720904.USD","LU0170899867.USD","LU0321505439.SGD","LU1066053197.SGD","SG9999002232.USD","SG9999001176.USD","LU0456855351.SGD","SG9999011175.SGD","LU1894683348.USD","BK4007","LU1057294990.SGD","LU0985481810.HKD","IE00B19Z3B42.SGD","BK4592","LU1894683264.USD","LU0225284248.USD","LU0321505868.SGD","BK4581"],"gpt_icon":1},{"id":"2591966754","title":"中国药企口服 GLP-1 超 20 亿美元授权辉瑞；正大天晴全球首个 CDK2/4/6 抑制剂获批上市｜Insight 新药周报","url":"https://stock-news.laohu8.com/highlight/detail?id=2591966754","media":"丁香园 Insight 数据库","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591966754?lang=zh_cn&edition=full","pubTime":"2025-12-14 13:48","pubTimestamp":1765691311,"startTime":"0","endTime":"0","summary":"伊奈利珠单抗本次gMG 新适应症的获批主要基于其全球关键性 Ⅲ 期试验 MINT 的积极结果。其中 MuSK+组随访 26 周，AChR+组随访 52 周。该申请此前已获 FDA 优先审查资格。临床试验动态1、德睿智药：口服小分子 GLP-1 首次启动 III 期临床12 月 10 日，德睿智药在 ClinicalTrials 官网登记了一项MDR-001 针对肥胖或超重受试者的 III 期临床。公开资料显示，这是该药启动的首个 III 期。该临床试验的目标是确定口服药物 MDR-001 是否能够改善超重或肥胖成年参与者的体重管理。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251214135346a4493885&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251214135346a4493885&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0122379950.USD","SG9999003800.SGD","LU0289739699.SGD","SGXZ57979304.SGD","LU0306807586.USD","BK4585","LU0321505868.SGD","SG9999011175.SGD","LU0058720904.USD","LU1883839398.USD","LU0170899867.USD","LU0225284248.USD","BK4007","LU1894683264.USD","LU1023059063.AUD","IE00B19Z3B42.SGD","BK4592","IE00BBT3K403.USD","SG9999001176.SGD","BK4533","IE00B19Z3581.USD","BK4599","SG9999002232.USD","LU1066051498.USD","IE000M9KFDE8.USD","LU0234572021.USD","LU0225771236.USD","IE0002270589.USD","IE00BLSP4239.USD","IE00BLSP4452.SGD","SG9999001176.USD","LU0985481810.HKD","BK4144","BK4568","LU1057294990.SGD","SG9999002224.SGD","GLP","LU1066053197.SGD","BK4588","BK4550","BK4590","PFE","LU1894683348.USD","LU0868494617.USD","BK4581","LU0321505439.SGD","SG9999013999.USD","LU0306806265.USD","BK4534","LU0456855351.SGD"],"gpt_icon":1},{"id":"2590097795","title":"2025年药企全球裁员潮上10000人，辉瑞也宣布裁200多人！","url":"https://stock-news.laohu8.com/highlight/detail?id=2590097795","media":"药械VIP","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590097795?lang=zh_cn&edition=full","pubTime":"2025-12-12 19:34","pubTimestamp":1765539287,"startTime":"0","endTime":"0","summary":"2025年12月10日，辉瑞将在瑞士裁减200多个岗位，将当地员工数量从约300人缩减至约70人，此举是其多年成本削减计划及瑞士业务整体调整的一部分。报道称在拉尔接手后，其业务职责范围有所收窄。回溯今年，5月裁员143人，7月裁员87人，加上此次，仅在南旧金山的裁员总数已达348人。更令人震惊的是，自2024年4月以来，基因泰克已裁员800多人。诺德宣布：减肥药巨头诺和诺德宣布，将在全球范围内裁员约9000人。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251212204350a69c06a4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251212204350a69c06a4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00BBT3K403.USD","LU0170899867.USD","SGXZ57979304.SGD","LU1883839398.USD","LU0058720904.USD","LU0306806265.USD","SG9999001176.SGD","LU0289739699.SGD","IE0002270589.USD","BK4533","IE00BKVL7J92.USD","BK4588","IE00B19Z3581.USD","LU0225284248.USD","IE00B19Z3B42.SGD","SG9999002232.USD","SG9999013999.USD","IE000M9KFDE8.USD","LU1066051498.USD","LU0456855351.SGD","LU1894683348.USD","SG9999001176.USD","LU1093756168.USD","LU0306807586.USD","LU1023059063.AUD","BK4534","LU1093756325.SGD","NVO","LU0154236417.USD","IE00BZ1G4Q59.USD","LU0225771236.USD","SG9999011175.SGD","LU1066053197.SGD","BK4532","IE00BLSP4452.SGD","LU0985481810.HKD","SG9999003800.SGD","LU0234572021.USD","LU1057294990.SGD","LU0321505439.SGD","IE00BLSP4239.USD","BK4550","SG9999002224.SGD","LU1894683264.USD","BK4581","LU0868494617.USD","BK4568","PFE","BK4592","BK4599"],"gpt_icon":0},{"id":"2590725265","title":"巨头卷向“三重靶点”减重药，国内价格战即将打响","url":"https://stock-news.laohu8.com/highlight/detail?id=2590725265","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590725265?lang=zh_cn&edition=full","pubTime":"2025-12-12 17:36","pubTimestamp":1765532204,"startTime":"0","endTime":"0","summary":"巨头押注“三重靶点”减重药当地时间12月11日，礼来发布数据称，该公司在研的新一代GLP-1类减重药retatrutide在一项后期临床试验中帮助患者减重近29%。目前礼来的替尔泊肽不同剂量可帮助患者减重15%至21%。届时，礼来与竞争对手诺和诺德的竞争将延伸至口服减重药领域。与糖尿病药物相比，用于减重适应症的治疗药物的定价通常较高。而随着大量仿制药的上市，2026年，一场GLP-1药物的价格战也即将打响。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251212173720a69ba0b2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251212173720a69ba0b2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1057294990.SGD","SG9999011175.SGD","LU1894683264.USD","LU1093756325.SGD","LU0234572021.USD","BK4592","LU1066053197.SGD","SG9999013999.USD","LU1093756168.USD","SGXZ57979304.SGD","BK4007","LU0289739699.SGD","LU0321505439.SGD","LU0321505868.SGD","LU0170899867.USD","IE00BZ1G4Q59.USD","BK4599","LU1894683348.USD","BK4160","LU0122379950.USD","PFE","LU0456855351.SGD","BK4588","LU0058720904.USD","03933","SG9999001176.SGD","NVO","BK4532","IE00B19Z3B42.SGD","BK4550","LU1066051498.USD","SG9999001176.USD","IE000M9KFDE8.USD","LU1883839398.USD","IE00B19Z3581.USD","IE00BBT3K403.USD","SG9999002224.SGD","SG9999002232.USD","LU0306807586.USD","01801","BK4585","GIPR","LU0985481810.HKD","BK4581","LU0225771236.USD","SG9999003800.SGD","LU0154236417.USD","IE0002270589.USD","BK4534","BK4568","IE00BLSP4452.SGD","IE00BKVL7J92.USD"],"gpt_icon":1},{"id":"2590552264","title":"辉瑞拟在瑞士裁员逾200人","url":"https://stock-news.laohu8.com/highlight/detail?id=2590552264","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590552264?lang=zh_cn&edition=full","pubTime":"2025-12-11 09:06","pubTimestamp":1765415200,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"ff5064eb621567456e415b4b163d2eed","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU0306806265.USD","LU1066053197.SGD","LU0234572021.USD","LU1023059063.AUD","LU0306807586.USD","LU0122379950.USD","BK4585","SG9999002232.USD","BK4007","PFE","LU0321505439.SGD","LU1057294990.SGD","BK4550","LU0868494617.USD","SG9999001176.USD","BK4599","LU0225284248.USD","LU0170899867.USD","LU0321505868.SGD","IE0002270589.USD","BK4533","BK4592","LU0058720904.USD","BK4534","SG9999013999.USD","LU1066051498.USD","LU1894683348.USD","IE000M9KFDE8.USD","LU0225771236.USD","BK4581","IE00B19Z3581.USD","SG9999011175.SGD","LU1883839398.USD","SG9999002224.SGD","SG9999003800.SGD","SGXZ57979304.SGD","BK4568","IE00BBT3K403.USD","IE00BLSP4452.SGD","LU0456855351.SGD","LU0985481810.HKD","BK4588","IE00B19Z3B42.SGD","IE00BLSP4239.USD","LU0289739699.SGD","SG9999001176.SGD","LU1894683264.USD"],"gpt_icon":0},{"id":"1116429656","title":"辉瑞将在年底前将瑞士员工人数从300减少至约70","url":"https://stock-news.laohu8.com/highlight/detail?id=1116429656","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1116429656?lang=zh_cn&edition=full","pubTime":"2025-12-11 00:31","pubTimestamp":1765384261,"startTime":"0","endTime":"0","summary":"辉瑞将在年底前将瑞士的员工人数从300减少至约70。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"ff5064eb621567456e415b4b163d2eed","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0225284248.USD","PFE","SG9999011175.SGD","LU0321505439.SGD","LU0289739699.SGD","LU0306806265.USD","SGXZ57979304.SGD","SG9999013999.USD","SG9999002224.SGD","BK4550","BK4588","SG9999001176.SGD","LU1894683348.USD","IE000M9KFDE8.USD","SG9999001176.USD","BK4585","IE00BLSP4452.SGD","LU0234572021.USD","SG9999003800.SGD","BK4533","BK4581","LU0170899867.USD","LU1883839398.USD","IE0002270589.USD","BK4568","IE00BBT3K403.USD","IE00BLSP4239.USD","LU1894683264.USD","BK4592","IE00B19Z3B42.SGD","LU0868494617.USD","LU0225771236.USD","BK4534","LU0122379950.USD","SG9999002232.USD","BK4007","LU0321505868.SGD","LU0456855351.SGD","LU1057294990.SGD","LU1066053197.SGD","LU1066051498.USD","LU1023059063.AUD","IE00B19Z3581.USD","LU0306807586.USD","LU0985481810.HKD","LU0058720904.USD","BK4599"],"gpt_icon":0},{"id":"1197740374","title":"Tukysa加入一线维持治疗使Her2+转移性乳腺癌患者的中位无进展生存期延长超过8个月","url":"https://stock-news.laohu8.com/highlight/detail?id=1197740374","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1197740374?lang=zh_cn&edition=full","pubTime":"2025-12-10 21:19","pubTimestamp":1765372789,"startTime":"0","endTime":"0","summary":"Tukysa加入一线维持治疗使Her2+转移性乳腺癌患者的中位无进展生存期延长超过8个月。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0122379950.USD","LU1057294990.SGD","LU0321505439.SGD","SG9999001176.SGD","SGXZ57979304.SGD","LU0306807586.USD","LU0234572021.USD","SG9999011175.SGD","LU0225771236.USD","IE00B19Z3B42.SGD","LU0985481810.HKD","BK4599","LU0456855351.SGD","LU1894683264.USD","PFE","BK4533","IE00BBT3K403.USD","BK4007","IE0002270589.USD","LU1066053197.SGD","BK4581","BK4568","LU0170899867.USD","LU0225284248.USD","LU0868494617.USD","LU1066051498.USD","BK4592","BK4588","IE000M9KFDE8.USD","SG9999002232.USD","IE00BLSP4452.SGD","LU1894683348.USD","LU1023059063.AUD","LU1883839398.USD","LU0289739699.SGD","BK4585","SG9999003800.SGD","SG9999001176.USD","LU0306806265.USD","BK4550","IE00BLSP4239.USD","SG9999002224.SGD","BK4534","IE00B19Z3581.USD","SG9999013999.USD","LU0321505868.SGD","LU0058720904.USD"],"gpt_icon":0},{"id":"1109987002","title":"辉瑞：Tukysa、曲妥珠单抗与珀妥珠单抗联用显示可控的安全性作为一线维持治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=1109987002","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1109987002?lang=zh_cn&edition=full","pubTime":"2025-12-10 21:19","pubTimestamp":1765372745,"startTime":"0","endTime":"0","summary":"辉瑞：Tukysa、曲妥珠单抗与珀妥珠单抗联用显示可控的安全性作为一线维持治疗","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1066053197.SGD","BK4581","SGXZ57979304.SGD","IE00BLSP4239.USD","SG9999001176.USD","SG9999001176.SGD","BK4550","LU0321505868.SGD","LU1057294990.SGD","SG9999011175.SGD","LU0456855351.SGD","BK4585","LU1894683264.USD","LU1894683348.USD","IE00BLSP4452.SGD","BK4534","LU0306807586.USD","LU0868494617.USD","LU0306806265.USD","BK4599","LU0122379950.USD","SG9999013999.USD","LU0289739699.SGD","SG9999003800.SGD","IE00BBT3K403.USD","LU0225771236.USD","LU0170899867.USD","LU0058720904.USD","PFE","SG9999002224.SGD","IE00B19Z3B42.SGD","BK4588","BK4007","LU0234572021.USD","SG9999002232.USD","BK4568","BK4592","LU0225284248.USD","IE000M9KFDE8.USD","IE0002270589.USD","LU1883839398.USD","LU0321505439.SGD","IE00B19Z3581.USD","LU0985481810.HKD","LU1066051498.USD","LU1023059063.AUD","BK4533"],"gpt_icon":0},{"id":"1145215489","title":"辉瑞：Tukysa、曲妥珠单抗与帕妥珠单抗联合使用在三期研究中相比曲妥珠单抗与帕妥珠单抗单独使用将疾病进展/死亡的风险降低了36%","url":"https://stock-news.laohu8.com/highlight/detail?id=1145215489","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1145215489?lang=zh_cn&edition=full","pubTime":"2025-12-10 21:18","pubTimestamp":1765372700,"startTime":"0","endTime":"0","summary":"辉瑞：Tukysa、曲妥珠单抗与帕妥珠单抗联合使用在三期研究中相比曲妥珠单抗与帕妥珠单抗单独使用将疾病进展/死亡的风险降低了36%","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0225284248.USD","LU0321505439.SGD","BK4568","SG9999002224.SGD","LU0234572021.USD","BK4550","SG9999011175.SGD","IE00B19Z3581.USD","BK4007","IE0002270589.USD","IE00BLSP4239.USD","BK4588","LU0306807586.USD","BK4592","LU1066051498.USD","BK4599","BK4581","PFE","LU1057294990.SGD","IE00BBT3K403.USD","SG9999001176.SGD","LU0225771236.USD","SG9999003800.SGD","SG9999013999.USD","IE00B19Z3B42.SGD","LU0985481810.HKD","SGXZ57979304.SGD","BK4534","LU1894683264.USD","SG9999001176.USD","LU0058720904.USD","LU0170899867.USD","BK4585","IE000M9KFDE8.USD","LU0122379950.USD","LU1023059063.AUD","LU0306806265.USD","IE00BLSP4452.SGD","LU0456855351.SGD","LU1883839398.USD","SG9999002232.USD","LU0289739699.SGD","LU1066053197.SGD","LU1894683348.USD","BK4533","LU0868494617.USD","LU0321505868.SGD"],"gpt_icon":0},{"id":"1172700752","title":"辉瑞：关键次要终点整体生存率在分析时未成熟，但与Tukysa相比显示出改善的数值趋势","url":"https://stock-news.laohu8.com/highlight/detail?id=1172700752","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1172700752?lang=zh_cn&edition=full","pubTime":"2025-12-10 21:16","pubTimestamp":1765372611,"startTime":"0","endTime":"0","summary":"辉瑞：关键次要终点整体生存率在分析时未成熟，但与Tukysa相比显示出改善的数值趋势","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1066051498.USD","LU0170899867.USD","IE000M9KFDE8.USD","LU0058720904.USD","IE00BLSP4452.SGD","BK4550","LU0868494617.USD","BK4534","BK4568","LU0321505439.SGD","LU0456855351.SGD","IE00B19Z3581.USD","SG9999002224.SGD","IE0002270589.USD","LU1883839398.USD","LU1894683348.USD","LU0122379950.USD","IE00B19Z3B42.SGD","BK4585","SG9999001176.USD","LU0225771236.USD","LU0289739699.SGD","SG9999013999.USD","LU0306807586.USD","LU1066053197.SGD","BK4588","SG9999001176.SGD","IE00BLSP4239.USD","BK4533","BK4592","LU0234572021.USD","LU1023059063.AUD","IE00BBT3K403.USD","SG9999003800.SGD","SG9999002232.USD","BK4581","LU0321505868.SGD","SGXZ57979304.SGD","BK4007","BK4599","SG9999011175.SGD","LU0306806265.USD","LU0985481810.HKD","LU0225284248.USD","LU1894683264.USD","LU1057294990.SGD","PFE"],"gpt_icon":0},{"id":"2590932977","title":"辉瑞通过高达21亿美元的交易扩展肥胖症产品线","url":"https://stock-news.laohu8.com/highlight/detail?id=2590932977","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590932977?lang=zh_cn&edition=full","pubTime":"2025-12-10 04:34","pubTimestamp":1765312440,"startTime":"0","endTime":"0","summary":"辉瑞（PFE）周二尾盘下跌1.4%，此前该公司通过一笔最高可达21亿美元的交易来扩展其肥胖症药物管线，与药友制药（YaoPharma）达成GLP-1药物YP05002独家合作与许可协议。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：张俊 SF065","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2025-12-10/doc-inhahafr0867734.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU1066053197.SGD","LU0225771236.USD","LU0234572021.USD","IE00B19Z3B42.SGD","BK4592","SG9999001176.USD","LU0306806265.USD","LU0170899867.USD","BK4581","SG9999011175.SGD","IE00BLSP4239.USD","SG9999013999.USD","BK4585","BK4599","LU1023059063.AUD","IE0002270589.USD","IE00BLSP4452.SGD","IE000M9KFDE8.USD","PFE","BK4550","LU0321505439.SGD","BK4568","SG9999001176.SGD","BK4588","IE00B19Z3581.USD","LU0456855351.SGD","LU1066051498.USD","LU1894683264.USD","SGXZ57979304.SGD","LU0985481810.HKD","IE00BBT3K403.USD","SG9999002232.USD","LU0289739699.SGD","LU1883839398.USD","LU0225284248.USD","LU0306807586.USD","LU0868494617.USD","LU0058720904.USD","BK4534","LU1057294990.SGD","SG9999003800.SGD","LU0122379950.USD","LU1894683348.USD","SG9999002224.SGD","BK4533","LU0321505868.SGD","BK4007"],"gpt_icon":0},{"id":"2590346711","title":"辉瑞(PFE)盘前升近1% 与药友制药签订GLP-1R独家许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2590346711","media":"金吾财讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590346711?lang=zh_cn&edition=full","pubTime":"2025-12-09 20:59","pubTimestamp":1765285163,"startTime":"0","endTime":"0","summary":"金吾财讯 | 辉瑞(PFE)盘前股价小幅上扬，暂升0.81%，报25.98美元。复星医药控股子公司药友制药与辉瑞于2025年12月9日签订《许可协议》，药友制药就口服小分子胰高血糖素样肽-1受体（GLP-1R）激动剂（包括YP05002）及含有该活性成分的产品授予辉瑞于全球范围及领域（人类、动物所有适应症的治疗、诊断及预防）独家开发、使用、生产及商业化权利。药友制药将有权获得不可退还的首付款15,000万美元及至多35,000万美元的开发里程碑款项。另据报道公司与药明康德达成独家合作及许可协议。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250107/YjVhOWQ5NzA2M2E1Yzc2MTczNjIzNzY5MDQ1Ng==.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/YjVhOWQ5NzA2M2E1Yzc2MTczNjIzNzY5MDQ1Ng==.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"295201","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0321505868.SGD","SG9999003800.SGD","BK4007","LU0122379950.USD","BK4588","LU1023059063.AUD","LU0225284248.USD","IE000M9KFDE8.USD","LU0306806265.USD","SG9999001176.SGD","IE00B19Z3581.USD","LU0985481810.HKD","LU1894683348.USD","BK4533","SG9999001176.USD","SG9999002224.SGD","BK4534","IE00B19Z3B42.SGD","IE00BBT3K403.USD","IE00BLSP4239.USD","LU1066053197.SGD","LU1883839398.USD","LU1057294990.SGD","BK1574","IE0002270589.USD","SG9999013999.USD","SGXZ57979304.SGD","LU0456855351.SGD","LU0234572021.USD","LU0170899867.USD","LU0225771236.USD","SG9999002232.USD","BK4590","BK4568","LU0321505439.SGD","BK4585","PFE","BK4599","BK4550","IE00BLSP4452.SGD","SG9999011175.SGD","BK4581","LU1894683264.USD","LU1066051498.USD","LU0058720904.USD","LU0289739699.SGD","BK4592","LU0868494617.USD","LU0306807586.USD","BK1191","BK4144"],"gpt_icon":0},{"id":"2589385703","title":"礼来(LLY.US)、强生(JNJ.US)与辉瑞(PFE.US)拓展中国市场：旗下创新药物纳入首版商保目录","url":"https://stock-news.laohu8.com/highlight/detail?id=2589385703","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589385703?lang=zh_cn&edition=full","pubTime":"2025-12-08 11:41","pubTimestamp":1765165294,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，礼来、辉瑞和强生在中国首个创新药物目录中占据了一席之地，开辟了新的市场渠道，提高了昂贵尖端疗法的销售前景。这些药品涵盖多种疾病，包括癌症、阿尔茨海默病以及罕见遗传性疾病。随着中国人口老龄化，对癌症、糖尿病、痴呆症等疾病治疗药物的需求日益增长，将这些药物纳入医保体系或可减轻国家医保的负担。BeOne Medicines是唯一一家有两款药物上榜的公司。政府并未立即公布平均折扣幅度。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1378669.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["JNJ","LU2129689605.HKD","LU1032955483.USD","LU2417539215.USD","LU1267930730.SGD","LU0203347892.USD","LU1261432733.SGD","LU1868836591.USD","LU0456855351.SGD","LU1221951129.SGD","IE00BKVL7J92.USD","LU0889566641.SGD","LU0122379950.USD","BK4516","IE00B1XK9C88.USD","LU0316494557.USD","LU0471298694.HKD","LU0006306889.USD","LU0820561818.USD","LU1974910355.USD","IE0034235303.USD","LU2265009873.SGD","IE00BVYPNW00.USD","IE0004445015.USD","IE00BKDWB100.SGD","LU1989771016.USD","BK4504","IE00BLSP4452.SGD","LU1244550494.USD","LU2750360641.GBP","LU2063271972.USD","IE00BFTCPJ56.SGD","LU2168564149.EUR","LU0985481810.HKD","LU2106854487.HKD","LU2746668461.USD","LU1064131342.USD","IE00B19Z3B42.SGD","LU2361045086.USD","LU0289739699.SGD","LU0466842654.USD","LU0320765646.SGD","LU1732799900.SGD","LU1430594728.SGD","LU0114720955.EUR","IE00BZ1G4Q59.USD","LU0256863811.USD","IE0009355771.USD","LU2324357040.USD","IE00B775H168.HKD","LU2461242641.AUD","LU1506573853.SGD","LU2133065610.SGD","LU2237443978.SGD","LU1894683264.USD","LU2430703095.HKD","LU0079474960.USD","IE00BDGV0183.EUR","LU1093756168.USD","IE00BVYPNV92.GBP","LU1623119135.USD","SG9999014906.USD","SGXZ51526630.SGD","IE00BFXG1179.USD","BK1161","BK4568","IE0005OL40V9.USD","LU0061475181.USD","LU2112291526.USD","LLY","IE00BKPKM429.USD","LU2168564065.EUR","LU2211815571.USD","LU0320765059.SGD","LU0708995401.HKD","LU2430703178.SGD","LU0353189680.USD","SG9999018865.SGD","IE00BJLML261.HKD","BK4007","IE00BLSP4239.USD","LU0823434740.USD","DRAG","LU0943347566.SGD","LU1069344957.HKD","BK4559","LU1894683348.USD","LU2456880835.USD","LU1718418525.SGD","IE00B1BXHZ80.USD","SG9999013999.USD","LU1267930813.SGD","LU1732800096.USD","LU0345769631.USD","IE00B7SZLL34.SGD","IE00BN29S564.USD","LU2168564222.USD","LU2237438978.USD","IE00BFSS7M15.SGD","LU1366192091.USD","LU0882574055.USD","LU1162221912.USD","LU1868836914.USD","IE00BK4W5M84.HKD","LU0225771236.USD","IE00BJT1NW94.SGD","LU1804176565.USD","LU0058720904.USD","LU1093756325.SGD","LU1496350502.SGD","LU0820561909.HKD","LU1585245621.USD","LU0225284248.USD","IE00B7KXQ091.USD","LU1244550221.USD","BK4581","LU1674673691.USD","LU1712237335.SGD","LU2357305700.SGD","IE00B2B36J28.USD","LU2505996681.GBP","SG9999003800.SGD","SGXZ99366536.SGD","LU2592432038.USD","LU2746668974.SGD","LU0170899867.USD","LU1127390331.HKD","LU0203345920.USD","LU1720051017.SGD","ASHR","BK4532","LU1280957306.USD","LU2471134523.USD","LU0471298777.SGD","LU0912757837.SGD","IE00B3T34201.USD","LU1074936037.SGD","LU1551013425.SGD","LU2360106947.USD","FXI","SG9999002224.SGD","LU2430703251.USD","LU2471134796.USD","CHAU","BK4534","LU0868494617.USD","SG9999001440.SGD","IE00BFSS8Q28.SGD","SG9999018857.SGD","SGXZ81514606.USD","LU0234570918.USD","LU0306806265.USD","GB00BDT5M118.USD","IE00BGHQF631.EUR","SGXZ57979304.SGD","LU0234572021.USD","IE00BK4W5L77.USD","LU0321505439.SGD","LU2236285917.USD","ASHS","PFE","LU1221951046.USD","SGXZ31699556.SGD","LU0096364046.USD","LU0345770308.USD","LU2237443465.HKD","IE0002270589.USD","LU0353189763.USD","BK1574","IE00BJJMRZ35.SGD","LU1323610961.USD","IE00BBT3K403.USD","IE0004445239.USD","SG9999015978.USD","IE00B4R5TH58.HKD","BK4533","LU2168564495.EUR","LU1548497426.USD","LU0354030511.USD","LU1914381329.SGD","LU2505996509.AUD","LU2361044949.HKD","LU2552382058.USD","LU0098860793.USD","IE00BWXC8680.SGD","LU0266013472.USD","LU0640476718.USD","CQQQ","LU0795875169.SGD","LU1868837136.USD","LU2602419157.SGD","SG9999017495.SGD","LU0203202063.USD","LU0320765992.SGD","LU1035775433.USD","LU2237443549.SGD","LU2264538146.SGD","SG9999014914.USD","LU0198837287.USD","KWEB","BK4592","LU1066051811.HKD","LU0256863902.USD","SG9999002232.USD","LU2552382215.SGD","LU1244550577.SGD","LU0354030438.USD","IE000M9KFDE8.USD","CWEB","LU2750360997.AUD","LU2023250504.SGD","LU0689472784.USD","LU1674673428.USD","IE00BSNM7G36.USD","LU0070217475.USD","LU0823416689.USD","SG9999015945.SGD","SG9999015986.USD","LU1988902786.USD","LU2471134879.HKD","LU1929549753.HKD","LU0823434583.USD","IE00B4JS1V06.HKD","LU2491050071.SGD","LU2237443895.HKD","IE00B19Z3581.USD","LU0321505868.SGD","LU1778281490.HKD","LU1883839398.USD","LU2108987350.USD","LU0985320562.USD","LU1023059063.AUD","LU1935042991.SGD","LU1061106388.HKD","SG9999014880.SGD","BK4550","LU0109394709.USD","LU0432979614.USD","LU2129689431.USD","LU0323591593.USD","BK4614","IE00BJJMRX11.SGD","LU1066051225.USD","LU1057294990.SGD","LU2089984988.USD","LU0792757196.USD","LU1059921491.USD","SG9999011175.SGD","LU2087625088.SGD","LU0786609619.USD","LU1066051498.USD","LU1551013342.USD","LU2237443382.USD","LU2491050154.USD","BK4585","LU0385154629.USD","LU1032466523.USD","IE00BJJMRY28.SGD","LU2129689514.USD","LU2237443622.USD","LU0097036916.USD","IE00B42XCP33.USD","BK4588","LU0203201768.USD","LU2468319806.SGD","LU0238689110.USD","LU1917777945.USD","LU0106261372.USD","LU0306807586.USD","MCHI","LU2552382132.HKD","LU1291159041.SGD","LU0795875086.SGD","IE0002141913.USD","SG9999001176.SGD","LU0109391861.USD","LU2168563687.JPY","LU2471134952.CNY","LU0345769128.USD","LU1868837300.USD","LU1983299246.USD","LU1868836757.USD","IE00B3PB1722.GBP","LU0882574139.USD","LU0345770993.USD","BK4599","LU2347655156.SGD","LU1066053197.SGD","SG9999015952.SGD","LU0889565916.HKD","LU1814569148.SGD","LU0094547139.USD","LU2462157665.USD","SG9999014898.SGD","LU0417517546.SGD","LU0672654240.SGD","LU2491049909.HKD","SG9999001176.USD","LU1720051108.HKD","IE00BN8TJ469.HKD","LU1232071149.USD","LU1196500208.SGD","LU2361044865.SGD"],"gpt_icon":1},{"id":"2589801206","title":"辉瑞制药思福诺纳入最新国家医保药品目录","url":"https://stock-news.laohu8.com/highlight/detail?id=2589801206","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589801206?lang=zh_cn&edition=full","pubTime":"2025-12-08 08:02","pubTimestamp":1765152148,"startTime":"0","endTime":"0","summary":null,"market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU0225284248.USD","PFE","SG9999011175.SGD","LU0321505439.SGD","LU0289739699.SGD","LU0306806265.USD","SGXZ57979304.SGD","SG9999013999.USD","SG9999002224.SGD","BK4550","BK4588","SG9999001176.SGD","LU1894683348.USD","IE000M9KFDE8.USD","SG9999001176.USD","BK4585","IE00BLSP4452.SGD","LU0234572021.USD","SG9999003800.SGD","BK4533","BK4581","LU0170899867.USD","LU1883839398.USD","IE0002270589.USD","BK4568","IE00BBT3K403.USD","IE00BLSP4239.USD","LU1894683264.USD","BK4592","IE00B19Z3B42.SGD","LU0868494617.USD","LU0225771236.USD","BK4534","LU0122379950.USD","SG9999002232.USD","BK4007","LU0321505868.SGD","LU0456855351.SGD","LU1057294990.SGD","LU1066053197.SGD","BK1191","LU1023059063.AUD","LU1066051498.USD","BK1574","IE00B19Z3581.USD","LU0306807586.USD","LU0985481810.HKD","LU0058720904.USD","BK4599"],"gpt_icon":0},{"id":"1119121716","title":"Hympavzi®（Marstacimab）在有抑制剂的成人和青少年血友病A或B患者中，与按需治疗相比减少出血率93%","url":"https://stock-news.laohu8.com/highlight/detail?id=1119121716","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1119121716?lang=zh_cn&edition=full","pubTime":"2025-12-07 06:16","pubTimestamp":1765059406,"startTime":"0","endTime":"0","summary":"Hympavzi®（Marstacimab）在有抑制剂的成人和青少年血友病A或B患者中，与按需治疗相比减少了93%的出血。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z3581.USD","LU0306806265.USD","LU0321505868.SGD","LU0456855351.SGD","LU1883839398.USD","LU1023059063.AUD","SGXZ57979304.SGD","LU0234572021.USD","BK4007","BK4550","IE00BLSP4239.USD","LU0122379950.USD","LU0321505439.SGD","PFE","LU1894683348.USD","SG9999011175.SGD","LU1057294990.SGD","SG9999013999.USD","IE00BLSP4452.SGD","IE0002270589.USD","LU1066051498.USD","LU0985481810.HKD","IE00BBT3K403.USD","BK4585","BK4533","IE00B19Z3B42.SGD","LU0225771236.USD","LU0289739699.SGD","LU0058720904.USD","BK4588","LU0306807586.USD","LU0225284248.USD","BK4581","SG9999003800.SGD","SG9999001176.SGD","BK4592","LU0170899867.USD","LU1894683264.USD","SG9999002232.USD","BK4599","IE000M9KFDE8.USD","LU1066053197.SGD","SG9999002224.SGD","BK4568","SG9999001176.USD","BK4534","LU0868494617.USD"],"gpt_icon":0},{"id":"1186165748","title":"美股疫苗股大跌，FDA 官员提及新冠疫苗与年轻男性心脏疾病有关联","url":"https://stock-news.laohu8.com/highlight/detail?id=1186165748","media":"老虎资讯综合","labels":["corporation","movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1186165748?lang=zh_cn&edition=full","pubTime":"2025-12-02 08:25","pubTimestamp":1764635137,"startTime":"0","endTime":"0","summary":"在疫情期间，Prasad 因反对疫苗强制措施以及对新冠疫苗引发心肌炎风险的关注而在网上获得追随者。其他研究则发现，新冠感染导致心肌炎的风险高于接种疫苗。辉瑞和 BioNTech 共同研发了新冠疫苗 Comirnaty。两家公司均研发并销售新冠 mRNA 疫苗。这并非 Prasad 首次推动与 mRNA 新冠疫苗相关的变更。这位 FDA 官员还呼吁为疫苗临床试验设定不同的终点指标。","market":"us","thumbnail":"https://static.tigerbbs.com/424a61980d8d04f8172cdf5eafb309c0","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/424a61980d8d04f8172cdf5eafb309c0"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"f5a0c542474fbfdd95db309645c9c3a7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"美股疫苗股大跌，FDA 官员提及新冠疫苗与年轻男性心脏疾病有关联","news_tag":"corporation,movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DVAX","PFE","BNTX","MRNA"],"gpt_icon":1},{"id":"1146660340","title":"Valneva Se - 辉瑞计划在2026年向美国FDA提交生物许可证申请和向欧洲药品管理局提交上市授权申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1146660340","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1146660340?lang=zh_cn&edition=full","pubTime":"2025-11-26 14:03","pubTimestamp":1764136992,"startTime":"0","endTime":"0","summary":"Valneva Se - 辉瑞计划在2026年向美国FDA提交生物许可证申请和向欧洲药品管理局提交上市授权申请","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0289739699.SGD","LU0306806265.USD","LU0122379950.USD","LU0985481810.HKD","LU0225771236.USD","LU0321505868.SGD","BK4007","BK4585","SG9999013999.USD","BK4592","SG9999002232.USD","LU0456855351.SGD","BK4588","PFE","BK4550","LU1066051498.USD","LU1023059063.AUD","SG9999002224.SGD","IE00BBT3K403.USD","LU0868494617.USD","BK4568","IE00B19Z3B42.SGD","SGXZ57979304.SGD","BK4534","LU0321505439.SGD","LU0306807586.USD","SG9999001176.USD","LU0058720904.USD","LU1883839398.USD","LU1894683348.USD","SG9999011175.SGD","IE0002270589.USD","LU1894683264.USD","BK4533","IE00B19Z3581.USD","LU1057294990.SGD","SG9999001176.SGD","SG9999003800.SGD","IE00BLSP4239.USD","LU0234572021.USD","IE000M9KFDE8.USD","LU0170899867.USD","LU1066053197.SGD","BK4581","IE00BLSP4452.SGD","BK4599","LU0225284248.USD"],"gpt_icon":0},{"id":"2586425720","title":"古根海姆上调辉瑞目标价至35美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2586425720","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586425720?lang=zh_cn&edition=full","pubTime":"2025-11-25 17:34","pubTimestamp":1764063257,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["PFE","IE00BLSP4239.USD","SG9999001176.SGD","BK4581","IE000M9KFDE8.USD","SG9999001176.USD","LU0868494617.USD","IE00BBT3K403.USD","LU1894683264.USD","SG9999011175.SGD","SG9999002232.USD","LU1066051498.USD","BK4007","BK4585","LU0456855351.SGD","SG9999003800.SGD","LU0985481810.HKD","IE00B19Z3B42.SGD","LU0225771236.USD","BK4568","IE0002270589.USD","LU0321505439.SGD","SGXZ57979304.SGD","BK4599","LU0321505868.SGD","SG9999013999.USD","LU1066053197.SGD","SG9999002224.SGD","LU0289739699.SGD","BK4550","LU0225284248.USD","LU1057294990.SGD","BK4533","BK4534","BK4588","LU1023059063.AUD","LU0058720904.USD","LU0234572021.USD","LU0170899867.USD","IE00B19Z3581.USD","LU1894683348.USD","LU0306806265.USD","LU1883839398.USD","LU0122379950.USD","BK4592","LU0306807586.USD","IE00BLSP4452.SGD"],"gpt_icon":0},{"id":"1163182464","title":"Arvinas公布有关Vepdegestrant（Arv-471）临床开发项目的数据展示，参加2025年圣安东尼奥乳腺癌研讨会（Sabcs）","url":"https://stock-news.laohu8.com/highlight/detail?id=1163182464","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1163182464?lang=zh_cn&edition=full","pubTime":"2025-11-24 20:02","pubTimestamp":1763985764,"startTime":"0","endTime":"0","summary":"Arvinas公布有关Vepdegestrant（Arv-471）临床开发项目的数据展示，参加2025年圣安东尼奥乳腺癌研讨会（Sabcs）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0058720904.USD","IE000M9KFDE8.USD","SGXZ57979304.SGD","IE00B19Z3581.USD","BK4592","SG9999002232.USD","IE00BLSP4239.USD","LU1023059063.AUD","LU1057294990.SGD","BK4588","LU0868494617.USD","LU0289739699.SGD","IE0002270589.USD","SG9999001176.USD","LU1066053197.SGD","LU1883839398.USD","BK4581","LU0225284248.USD","IE00BBT3K403.USD","LU0306807586.USD","SG9999003800.SGD","ARVN","BK4533","BK4568","LU0321505868.SGD","LU0306806265.USD","LU1894683264.USD","SG9999001176.SGD","LU1894683348.USD","BK4599","SG9999013999.USD","LU0170899867.USD","BK4550","LU0321505439.SGD","IE00BLSP4452.SGD","LU0122379950.USD","SG9999002224.SGD","SG9999011175.SGD","BK4007","IE00B19Z3B42.SGD","LU0985481810.HKD","LU1066051498.USD","PFE","LU0234572021.USD","LU0225771236.USD","LU0456855351.SGD","BK4534","BK4585"],"gpt_icon":0},{"id":"2585319634","title":"辉瑞友瑞宁（马塔西单抗）在华获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2585319634","media":"南方财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585319634?lang=zh_cn&edition=full","pubTime":"2025-11-21 12:18","pubTimestamp":1763698705,"startTime":"0","endTime":"0","summary":"辉瑞友瑞宁（马塔西单抗）在华获批","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202511213571249897.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4533","BK4599","LU0321505439.SGD","IE00BLSP4239.USD","BK4585","PFE","LU0306807586.USD","SG9999013999.USD","IE00BLSP4452.SGD","LU0306806265.USD","LU0225771236.USD","BK4007","LU1023059063.AUD","LU1057294990.SGD","BK4568","LU1894683264.USD","LU0868494617.USD","BK4592","LU0985481810.HKD","BK4550","IE00BBT3K403.USD","LU0234572021.USD","SGXZ57979304.SGD","SG9999011175.SGD","LU1066053197.SGD","LU0321505868.SGD","IE0002270589.USD","SG9999001176.USD","IE00B19Z3581.USD","SG9999001176.SGD","SG9999002232.USD","SG9999003800.SGD","SG9999002224.SGD","BK4588","LU0122379950.USD","LU1883839398.USD","BK4581","LU0289739699.SGD","BK4534","IE000M9KFDE8.USD","LU0225284248.USD","LU1894683348.USD","LU0456855351.SGD","LU0170899867.USD","LU1066051498.USD","IE00B19Z3B42.SGD","LU0058720904.USD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.pfizer.com","stockEarnings":[{"period":"1week","weight":-0.0069},{"period":"1month","weight":-0.0008},{"period":"3month","weight":0.0829},{"period":"6month","weight":0.0534},{"period":"1year","weight":0.0189},{"period":"ytd","weight":-0.0256}],"compareEarnings":[{"period":"1week","weight":-0.0057},{"period":"1month","weight":-0.0024},{"period":"3month","weight":0.037},{"period":"6month","weight":0.142},{"period":"1year","weight":0.1281},{"period":"ytd","weight":0.1633}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"辉瑞公司于1942年6月2日根据特拉华州法律成立。公司是一家以研究为基础的全球性生物制药公司。公司运用科学和全球资源，通过发现、开发、制造和分销保健产品（包括创新药物和疫苗），为人们带来延长和显著改善其生活的疗法。公司在发达国家和新兴市场开展工作，致力于促进健康、预防、治疗和治愈这个时代最令人恐惧的疾病。公司与医疗保健提供商、政府和当地社区合作，支持并扩大在全球范围内获得可靠、负担得起的医疗保健服务。","yearOnYearQuotes":[{"month":1,"riseRate":0.444444,"avgChangeRate":0.001224},{"month":2,"riseRate":0.444444,"avgChangeRate":-0.007083},{"month":3,"riseRate":0.6,"avgChangeRate":0.014714},{"month":4,"riseRate":0.586957,"avgChangeRate":0.018253},{"month":5,"riseRate":0.5,"avgChangeRate":0.007748},{"month":6,"riseRate":0.5,"avgChangeRate":0.002798},{"month":7,"riseRate":0.478261,"avgChangeRate":0.011357},{"month":8,"riseRate":0.456522,"avgChangeRate":0.0002},{"month":9,"riseRate":0.456522,"avgChangeRate":0.004432},{"month":10,"riseRate":0.630435,"avgChangeRate":0.013042},{"month":11,"riseRate":0.695652,"avgChangeRate":0.028255},{"month":12,"riseRate":0.521739,"avgChangeRate":0.009254}],"exchange":"NYSE","name":"辉瑞","nameEN":"Pfizer"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"辉瑞(PFE)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供辉瑞(PFE)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"辉瑞,PFE,辉瑞股票,辉瑞股票老虎,辉瑞股票老虎国际,辉瑞行情,辉瑞股票行情,辉瑞股价,辉瑞股市,辉瑞股票价格,辉瑞股票交易,辉瑞股票购买,辉瑞股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"辉瑞(PFE)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供辉瑞(PFE)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}